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Background: Tuberculosis, the disease due to Mycobacterium tuberculosis, is an important cause of morbidity and
mortality in the elderly. Use of mouse models may accelerate insight into the disease and tests of therapies since
mice age thirty times faster than humans. However, the majority of TB research relies on inbred mouse strains, and
these results might not extrapolate well to the genetically diverse human population. We report here the first tests
of M. tuberculosis infection in genetically heterogeneous aging mice, testing if old mice benefit from rapamycin.
Findings: We find that genetically diverse aging mice are much more susceptible than young mice to M. tuberculosis,
as are aging human beings. We also find that rapamycin boosts immune responses during primary infection but fails
to increase survival.
Conclusions: Genetically diverse mouse models provide a valuable resource to study how age influences responses
and susceptibility to pathogens and to test interventions. Additionally, surrogate markers such as immune measures
may not predict whether interventions improve survival.
Keywords: Tuberculosis, Rapamycin, HET3, DO, Diversity outbred, Genetically diverse population, Early Secreted
Antigenic Target-6 (ESAT-6)Findings
Introduction
The importance of using genetically diverse experi-
mental animals to model human populations was de-
monstrated many years ago in aging research [1] to
avoid confusing a single genetic individual’s unique cha-
racteristics with those of the species. Here, we use two
models of genetically diverse mice to study susceptibility
to M. tuberculosis infection and immune responses to an
M. tuberculosis antigen, Early Secreted Antigenic Target-6
(ESAT-6), in old mice.
The first population is HET3 mice, the F2 progeny
from crossing CByB6F1/J F1 hybrid females (JAX stock
number 100009, [BALB/cByJ females and C57BL/6J
males]) with C3D2F1/J F1 hybrid males (JAX stock
number 100004, [C3H/HeJ females and DBA/2J males]).* Correspondence: gillian.beamer@tufts.edu
†Equal contributors
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unless otherwise stated.As defined by Roderick [2], the resultant “four way
cross” population is reproducible, and each HET3 mouse
is genetically unique but a full sibling of all other mice
in the population. We used HET3 mice in studies of
primary M. tuberculosis infection and aging and in a
rapamycin intervention.
The second population is Diversity Outbred (DO) mice
(JAX stock number 009376). DO mice are derived from
the eight parental inbred strains (A/J, C57BL/6J, 129S1/
SvImJ, NOD/ShiLtJ, NZO/HILtJ, CAST/EiJ, PWK/PhJ,
and WSB/EiJ) [3,4], and thus are more genetically diverse
than HET3 mice. We used aging DO mice to test immune
responses to ESAT-6 in the context of rapamycin
intervention.
In humans, age-related declines in T cell function [5] in-
crease risk of developing tuberculosis (TB) due to
reactivation of a latent infection or following primary in-
fection with M. tuberculosis [6,7]. T cell functions are also
defective in aging mice infected with M. tuberculosis
[8-10], making mouse models useful for testing if boostingl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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help protect the elderly against this deadly disease.
We tested whether rapamycin treatment alters acquired
immunity to primary M. tuberculosis infection and to vac-
cination with the M. tuberculosis protein antigen ESAT-6
plus an adjuvant. We chose rapamycin because it has mul-
tiple potential benefits for aging and infectious disease
models. Studies in the Harrison laboratory show rapamy-
cin improves acquired cellular and humoral immunity in
old mice but not young mice (unpublished). Additionally,
rapamycin also extends lifespan [11-13] and controls
energy/nutrient utilization of immune cells [14]. Further-
more, Jagganath et al. [15] demonstrated that rapamycin
co-administered with M. bovis BCG-vaccination enhanced
M. tuberculosis antigen-specific interferon-gamma (IFN-γ)
responses and reduced M. tuberculosis load in young,
C57BL/6 mice. However, genetically diverse mice, aged
mice, and survival were not tested. Here, rapamycin
boosted antigen-specific IFN-γ in genetically diverse aged
mice with primary M. tuberculosis infection (HET3 mice)
and following vaccination (DO mice), but did not alter
survival to M. tuberculosis primary infection. This shows
the importance of survival measures, which is highly rele-
vant to M. tuberculosis studies because correlates of pro-




Experiments were approved by The Jackson Laboratory
IACUC protocols (DEH02-01; DEH07-08; DEH95-01) and
Tufts University IACUC protocols (G2012-53; G2012-151).
For both institutions, approved criteria for euthanasia due
to morbidity included unresponsiveness, labored brea-
thing, sunken hips, difficulty walking, cachexia, or persis-
tent social isolation. Biosafety Level 3 work was approved
by Tufts University Institutional Biosafety Committee
registration (GRIA04).
Mice and rapamycin administration
Mice were bred, aged in-house until 22 months of age,
and treated with rapamycin at The Jackson Laboratory
(Bar Harbor, ME) as detailed [19]. Treatment was for
6 weeks followed by one month withdrawal; control
mice received chow alone. Rapamycin treatment on this
schedule enhances multiple aspects of immunity in old
but not young mice (unpublished, DH).
Infection with Mycobacterium tuberculosis
Female HET3 mice were shipped to the New England
Regional Biosafety Laboratory (Grafton MA) and acclimated
during the rapamycin withdrawal period. Fifty-one aging
(24.5 months) and 18 young (6 months) mice received
94 ± 30M. tuberculosis Erdman bacilli in the lungs using aCH Technologies® (Westwood, NJ) machine. Mice were
monitored daily. Prior to infection, mice were weighed
weekly. After infection, mice were weighed at least twice
per week. Data from 11 aging HET3 mice were censored
due to neoplasia (N = 8), hydrouterus (n = 2), or sudden
death with no gross lesions (N = 1). Thus, 40 aging HET3
mice gave useful data.
Vaccination with recombinant ESAT-6
Fifty-six female DO mice were fed rapamycin or control diet
as above, shipped to the Cummings School of Veterinary
Medicine (Grafton, MA) and acclimated during the rapa-
mycin withdrawal period. At 24.5 months of age, 36 DO
mice (18 rapamycin diet at 14 ppm; 18 control diet) were
vaccinated three times, two weeks apart, subcutaneously
with ESAT-6 or adjuvant as described [20]. Nine DO mice
(5 rapamycin at 14 ppm; 4 control diet) received the adju-
vant alone.
Whole blood interferon gamma release assays
Blood was collected from the submandibular vein of
HET3 mice prior to infection and monthly throughout.
Blood was obtained from the heart of DO mice following
euthanasia. ESAT-6 specific IFN-γ was quantified by
ELISA or by ELIPSOT [21] except that blood was di-
luted 1:5, not 1:10.
Flow cytometry
Blood was collected from the submandibular vein 6 weeks
prior to M. tuberculosis infection of HET 3 mice; red blood
cells were lysed and nucleated cells were counted. Forward
and side scatter profiles were adjusted to eliminate debris
and isotype controls used for gating. Naïve CD4 T cells
were defined as CD45.2+CD3+CD4+CD62LhiCD44lo using
the following antibodies: CD45.2 FITC clone 104.7; CD3ε
PE clone 145-2C11; CD4 Pacific Orange clone GK1.5;
CD62L PE-Cy7 clone Mel-14; CD44 APC-Cy7 clone
IM7.8. Samples were read using a four-laser/13-color BD
LSRII special order system (340551) analytical cytometer
(BDBiosciences, San Jose, CA) and analyzed by FlowJo
software at the Flow Cytometry Laboratory of The Jackson
Laboratory (Bar Harbor, ME). In DO mice, ESAT-6 spe-
cific CD4 T cell proliferation was assessed by intranuclear
incorporation of BrdU following manufacturer instruc-
tions (BrdU Flow Kit, BD Biosciences). Samples were read
and analyzed as described [21] except an AccuriC6 flow
cytometer was used.
Histology
Formalin-inflated lungs were fixed, processed, embedded
in paraffin, cut at 5 μm, and stained with hematoxylin and
eosin at the Cummings School of Veterinary Medicine
Histology Laboratory. Two serial sections, 100 μm apart,
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(GB) without knowledge of the groups.Statistical analyses
Using GraphPad Prism 6.4, data were analyzed for outliers
by ROUT and Grubb’s methods. No outliers were identi-
fied by ROUT. Grubb’s identified one outlier at 444 SFU.
This value was excluded because it was not clear whether
it reflected technical error or a true biological effect. Data
were then analyzed for the distribution. Data were not
normally distributed so Spearman correlation coefficients
were calculated. For Figure 1B, exponential and 4th degree
polynomial regression analyses were performed; the decay
of the rate of weight loss resulted in an exponential model,
written as f(x) = 0.5749 * e (−0.0122*x) with x representing
the time in days. The polynomial model (4th degree) is not
reported due to its tendency to overfit. Survival curves were
analyzed by Logrank analysis. Multigroup comparisons
were analyzed using one-way ANOVA with Tukey’sFigure 1 Aged HET3 mice are more susceptible to M. tuberculosis tha
female HET3 mice were euthanized when morbidity developed. Survival (A
(D), weight at euthanasia (E), and proportional weight loss (F) are shown. S
data were analyzed by Student’s t-tests, *p < 0.05, **p < 0.01. Data were cen
mice were censored.post-test. Significance for all tests was defined *p < 0.05,
**p < 0.01, ***p < 0.001, and ****p < 0.0001.
Results and discussion
Genetically diverse aging mice are more susceptible to
Mycobacterium tuberculosis than young
Mouse models of genetic diversity are becoming more
widely used [4,13,22-25]. A majority of M. tuberculosis
research in young and old mice has used the C57BL/6
inbred strain, with fewer studies using B6 hybrids or
other inbred strains such as Balb/c, C3H/HeJ, DBA/2,
CBA/J, I/St, and A/Sn [26]. Through these studies we
have learned valuable information regarding responses
to M. tuberculosis, characteristics of susceptible and re-
sistant strains, and genes that contribute to susceptibi-
lity. However, the allelic homozygosity of inbred strains
leads to expression of deleterious recessive genes, which
may affect results especially in aging studies (1). There-
fore, genetically diverse mouse models may be useful for
M. tuberculosis research.n young. M. tuberculosis infected old (N = 40) and young (N = 18),
), weights over time in old (B) and young (C) mice, peak body weight
urvival data were analyzed by Log rank test, ****p < 0.0001. Pairwise
sored for 11 old mice due to non-TB morbidity. No data from young
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mice are more susceptible to aerosolized M. tuberculosis
than young, with median survivals of 118 and 197 days in
aging and young mice, respectively (Figure 1A). A charac-
teristic of TB in mice and human beings is weight loss; in
fact, weight is a useful indicator of TB in mice because it
occurs before respiratory, motor, and social disturbances
[27]. And because weighing mice is non-invasive, repeated
measures can be performed on individual mice with little
stress. In aging HET3 mice, weight loss began earlier in
M. tuberculosis infection than in young mice (Figure 1B,C),
even though aging mice were heavier (Figure 1D,E).
Aging mice also lost relatively more weight due to TB
(Figure 1F).
Evidence of clinical disease began on average, 21 days
after M. tuberculosis infection in old mice; in contrast dis-
ease in young mice began, on average, 127 days after infec-
tion. This likely reflects better control of M. tuberculosis
bacilli, or better control of detrimental inflammation, in
young mice. The duration of disease was the same in aging
and young HET3 mice (85 ± 50 versus 88 ± 41 days, re-
spectively). Regardless of age, lungs eventually fill withFigure 2 Body weight, immune parameters, and survival in aging M.
infected aging mice (N = 40) (A) and the rate of weight loss (B) as compared
weight and survival (Spearman r −0.1082, p = 0.26) (A). A strong negative cor
(Spearman r −0.7123, p < 0.0001) with dashed lines showing the 95% confide
to infection and then after infection at monthly intervals to quantify the avera
correlation was identified between naïve CD4 T cells and survival (Spearman
significant correlation between ESAT-6 specific IFN-γ and survival (Spearman r
non-TB morbidity.inflammatory cells and variable necrosis in all mice (not
shown). Therefore, the main effect of old age appears to be
that disease onset occurs earlier.
We expected that body weight would positively cor-
relate with survival. However, this was not true for aging
HET3 mice (Figure 2A), but we did observe that the rate
of weight loss was the best indicator of TB disease pro-
gression, shown and modeled by an exponential decay
(Figure 2B). Although weight changes do not reflect spe-
cific immunologic or pathologic changes, the ability to
track body weight provides a foundation to identify bio-
markers that precede weight loss.
We explored relationships between survival and immu-
nity that may be important for resistance to M. tuberculosis.
Survival did not correlate with the total (not shown) or
naïve CD4 T cell numbers prior to infection (Figure 2C).
Survival correlated significantly with ESAT-6 specific IFN-γ
in HET3 mice but the correlation was weak (Figure 2D)
and some mice were clear exceptions.
In summary, our findings suggest that aged, genetically
diverse mice can model age-related susceptibility to
M. tuberculosis primary infection in humans. Although Ttuberculosis infected HET3 mice. Peak body weights of M. tuberculosis
to survival. There was no significant correlation between peak body
relation was identified between the rate of weight loss and survival
nce intervals (B). Blood was sampled to quantify naïve CD4 T cells prior
ge ESAT-6-specific IFN-γ responses for each mouse. No significant
r −0.2775, p < 0.08) (C), but there was a weak positive, statistically
0.3694, p < 0.02) (D). Data were censored for 11 old mice due to
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(shown by markedly increased susceptibility when these
molecules are absent in inbred mice [28,29]), in immune
competent aged HET3 mice, antigen-specific IFN-γ is a
positive but weak correlate of survival.
Rapamycin boosts antigen-specific interferon-gamma
responses
Interventions to improve the length and quality of life are
of interest, and HET3 mice are advantageous for research
and testing interventions because the population of sib-
lings is reproducible and results can be compared across
time and from different laboratories [13,19,30]. Fur-
thermore, rapamycin benefits multiple types of immuneFigure 3 Rapamycin enhances ESAT-6 responses to primary M. tuberc
untreated old HET3 mice were infected with M. tuberculosis by aerosol. Old D
ESAT-6 specific IFN-γ responses the blood of HET3 mice were quantified befo
mice, proliferating ESAT-6 specific CD4 T cells (B) and cells capable of ESAT-6
mice per group, reported as average + SEM, analyzed by one-way ANOVA, **presponses in old mice but not young mice (unpublished,
DH), and rapamycin could improve outcome to M. tuber-
culosis infection by enhancing innate or acquired immu-
nity. Rapamycin has beneficial effects on lifespan [11-13]
and controls metabolism of immune cells [14] impor-
tant for resistance to M. tuberculosis [28,29]. Rapamycin
also stimulates M. tuberculosis antigen-specific TH1 cells
[15,31] by inducing autophagy [32] which can eliminate
intracellular M. tuberculosis bacilli [33]. We thus tested
whether rapamycin enhanced immune responses to M. tu-
berculosis in aging mice. Indeed, rapamycin increased
ESAT-6-specific IFN-γ responses during M. tuberculosis
infection (Figure 3A). Rapamycin also increased ESAT-6-
specific proliferation, the numbers of IFN-γ producingulosis infection and to ESAT-6 vaccination. Rapamycin-treated and
O mice were vaccinated with ESAT-6 plus adjuvant or adjuvant alone.
re and after infection (A). Three weeks after the final vaccination of DO
specific IFN-γ (C, D) were determined by ELISPOT. Results are from 12–20
< 0.01, ***p < 0.001, NS not significant.
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cells (Figure 3B-D) when ESAT-6 was administered as a
vaccine. Whether these responses to ESAT-6 vaccination
improve control of M. tuberculosis bacillary growth or
prolong survival remains to be determined.
In summary, our results indicate that oral rapamycin
showed trends for enhancing ESAT-6 specific responses
in genetically diverse old mice. The variable statistical
significance likely reflects the relatively small sample
size, in particular with the vaccination studies in DO
mice. Although additional studies are needed, the find-
ing may be relevant for elderly people because oral de-
livery of agents is an attractive method to improve
immune function.
Rapamycin does not improve survival of aging mice with
primary M.tb infection
We next assessed whether rapamycin treatment improved
survival, delayed the onset of TB disease, or altered the
lung lesions during primary M. tuberculosis infection.
Rapamycin did not prolong survival or extend the median
survival (Figure 4A) or delay disease onset (not shown).Figure 4 Oral rapamycin does not improve survival of M. tuberculosis
Rapamycin treated (N = 37) and untreated (N = 13) old HET3 mice were inf
criteria were met (A). Lung sections were semi-quantitatively evaluated for ne
determined for each category (B). Examples of the microscopic lesions are shModest changes in lungs are attributable to rapamycin: a
slight reduction in the proportion of mice with marked
necrosis and neutrophil influx and a shift toward in-
creased lymphocytes (Figure 4B). Regardless, lung damage
in all mice was substantial, and thus, despite having poten-
tial benefits (on lifespan, cellular and humoral immunity,
autophagy), rapamycin in our model did not delay TB dis-
ease or extend survival in M. tuberculosis infected aged
HET3 mice regardless of immunologic changes or tissue
architectural changes.
We observed a trend for rapamycin-enhanced antigen-
specific responses (proliferation, IFN-γ) in the vaccin-
ation model. It is unknown whether rapamycin or the
enhanced immune responses can actually protect against
M. tuberculosis challenge in this model, but this is a logical
next step for future studies. However, clinical outcomes
and survival measures in mice are now even more import-
ant when testing interventional or preventative therapies
against M. tuberculosis infection because protective corre-
lates of immunity are not fully known [16-18]. This strat-
egy is necessary to assess the potential of rapamycin to
improve vaccination efficacy in elderly people.infected aged mice and minimally impacts lung lesions.
ected with aerosolized M. tuberculosis and euthanized when removal
crosis, neutrophils, and lymphocytes, and the proportion of mice was
own, magnified 200 times: necrosis (C); neutrophils (D); lymphocytes (E).
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